
A
carmustine
cephalo
docetaxel
mg132
vindesine
vinorelbine
jq1
acetylcysteine
amiodarone
bendro
gefitinib
gsk994854a
gw644007x
gw770249x
linsitinib
certinib
dasatinib
ensartinib
ly294002
quercetin
rapamycin
u0126
methotrexate
abexinostat
bazedoxifene
entinostat
m344
mocetinostat
pracinostat
quisinostat
verteporfin
ag879
cabozantinib
gw694590a
lyacator
loratadine
nategilinide
nebivolol
tyrphostin
sb253226
tanespimycin
afatinib
gsk1751853a
gw4587877a
ponatinib
thioridazine
bosutinib
pp2
tak632
zm447439
carfilzomib
harringtonine
olaparib
givinostat
panobinostat
aprepitant
becio
dronedarone
naftopidil
sp600125
bml259
dactolisib
trametinib
ulixertinib
Loewe
CI
Bliss
β_{obs}
α_2
Syn
Ant
B
DIP rate (h^{-1})
0.10
0.05
0.00
−0.05
−0.10
−0.15
SYN
ANT
UND
C
h1 = 1.0, h2 = 0.5
h1 = h2 = 1.0
h1 = 1.0, h2 = 2.0
Antagonistic
Synergistic
d2 conc. (linear)
d1 conc. (linear)
D
PC9
Melanoma
Median Loewe
Corr:-0.51
p-val:1e-3
Corr:-0.41
p-val:8e-4
$\sqrt{h_1 h_2}$
3e-1
1
2e1
E
panobinostat
methotrexate
$\ln\left(\frac{fA}{fU}\right)$
ln([d])
Percent Viability
MuSyC
CI
log10([d])